Twelve children came into this trial unable to hear a gas-powered lawn mower running next to them. That is what profound deafness means on paper: an average hearing threshold above 90 decibels. Some of them left the trial able to hear soft speech without any device at all. Three of them ended up with hearing in the normal range.
The therapy, called DB-OTO, was tested in an open-label, first-in-human study reported in the New England Journal of Medicine. It targets a specific and cruel form of inherited deafness. Children in the study carry mutations in the gene for otoferlin, a protein that sensory hair cells in the inner ear need to pass their signals along to the auditory nerve. The hair cells themselves are often fine. The wiring at the synapse is broken. Without otoferlin, sound gets converted but never sent.
Delivering a working gene to the cochlea
DB-OTO is built from two adeno-associated virus type 1 particles. The otoferlin gene is too large to fit inside a single AAV, so the researchers split the instructions across two viruses and let the cell reassemble the full protein. A hair-cell-specific promoter keeps the gene switched on only where it belongs. The whole package is infused directly into the cochlea, at a dose of 7.2 x 10^11 vector genomes per ear, in one or both ears.
The bar for success was deliberately clinical rather than academic. The primary endpoint asked whether, 24 weeks after the infusion, a child's average pure-tone threshold had dropped to 70 decibels or better. That number matters because it is roughly the point where a cochlear implant becomes avoidable and natural acoustic hearing becomes possible. Nine of the twelve children hit it. The same nine also showed an auditory brainstem response to a click at or below 90 decibels, meaning the signal was reaching the brain. The probability that both results happened by chance was about one in a billion.
What the children could actually do
Statistics on an audiogram are one thing. What the numbers translated into is more striking. Six of the treated children could hear soft speech without any assistive device. Three reached average normal hearing sensitivity, the kind most people are born with and never think about. For a condition where the standard path has been a surgically implanted cochlear device, hearing a whisper unaided is a different category of outcome.
The safety picture was reassuring within the limits of a small study. Sixty-seven adverse events occurred or worsened during or after treatment. None of them caused a child to drop out. Delivering anything into the delicate structures of the inner ear carries real risk, and the researchers tracked balance function alongside hearing, since the vestibular system shares that space.
Reasons to stay measured
This is a registrational study, but it is still twelve children with no control group and follow-up measured in months, not years. Three participants did not reach the hearing threshold, and the abstract does not explain why some responded and others did not. Durability is the open question that matters most. Gene therapies delivered to non-dividing cells can last a long time, but "can" is not "will," and nobody yet knows whether hearing gained at week 24 holds at year five or year fifteen. The therapy also only helps this one genetic cause. Otoferlin-related deafness is a small slice of all congenital hearing loss, so the approach does not generalize to the many children whose deafness comes from damaged hair cells rather than a broken synapse. The work was funded by Regeneron Pharmaceuticals, which developed the therapy.
Still, the direction is hard to miss. For decades, congenital deafness of this kind had one answer: an implant that bypasses the ear's own machinery. DB-OTO instead repairs the machinery. A child who receives a working copy of the otoferlin gene is not being routed around their biology. They are hearing with their own ear.
Comments